Assessing cognitive improvement in people with down syndrome

Important considerations for drug-efficacy trials

Fabian Fernandez, Roger H Reeves

Research output: Contribution to journalArticle

Abstract

Experimental research over just the past decade has raised the possibility that learning deficits connected to Down syndrome (DS) might be effectively managed by medication. In the current chapter, we touch on some of the work that paved the way for these advances and discuss the challenges associated with translating them. In particular, we highlight sources of phenotypic variability in the DS population that are likely to impact performance assessments. Throughout, suggestions are made on how to detect meaningful changes in cognitive– adaptive function in people with DS during drug treatment. The importance of within-subjects evaluation is emphasized.

Original languageEnglish (US)
Pages (from-to)335-380
Number of pages46
JournalHandbook of Experimental Pharmacology
Volume228
DOIs
StatePublished - 2015

Fingerprint

Drug therapy
Down Syndrome
Pharmaceutical Preparations
Cognition
Learning
Research
Population

Keywords

  • Adaptive
  • Behavior
  • Clinical trial
  • Cognition
  • Down syndrome
  • Drug treatment
  • Intellectual disability

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry
  • Medicine(all)

Cite this

@article{83a818285de0424292bc95cc301600a0,
title = "Assessing cognitive improvement in people with down syndrome: Important considerations for drug-efficacy trials",
abstract = "Experimental research over just the past decade has raised the possibility that learning deficits connected to Down syndrome (DS) might be effectively managed by medication. In the current chapter, we touch on some of the work that paved the way for these advances and discuss the challenges associated with translating them. In particular, we highlight sources of phenotypic variability in the DS population that are likely to impact performance assessments. Throughout, suggestions are made on how to detect meaningful changes in cognitive– adaptive function in people with DS during drug treatment. The importance of within-subjects evaluation is emphasized.",
keywords = "Adaptive, Behavior, Clinical trial, Cognition, Down syndrome, Drug treatment, Intellectual disability",
author = "Fabian Fernandez and Reeves, {Roger H}",
year = "2015",
doi = "10.1007/978-3-319-16522-6_12",
language = "English (US)",
volume = "228",
pages = "335--380",
journal = "Handbook of Experimental Pharmacology",
issn = "0171-2004",
publisher = "Springer Heidelberg",

}

TY - JOUR

T1 - Assessing cognitive improvement in people with down syndrome

T2 - Important considerations for drug-efficacy trials

AU - Fernandez, Fabian

AU - Reeves, Roger H

PY - 2015

Y1 - 2015

N2 - Experimental research over just the past decade has raised the possibility that learning deficits connected to Down syndrome (DS) might be effectively managed by medication. In the current chapter, we touch on some of the work that paved the way for these advances and discuss the challenges associated with translating them. In particular, we highlight sources of phenotypic variability in the DS population that are likely to impact performance assessments. Throughout, suggestions are made on how to detect meaningful changes in cognitive– adaptive function in people with DS during drug treatment. The importance of within-subjects evaluation is emphasized.

AB - Experimental research over just the past decade has raised the possibility that learning deficits connected to Down syndrome (DS) might be effectively managed by medication. In the current chapter, we touch on some of the work that paved the way for these advances and discuss the challenges associated with translating them. In particular, we highlight sources of phenotypic variability in the DS population that are likely to impact performance assessments. Throughout, suggestions are made on how to detect meaningful changes in cognitive– adaptive function in people with DS during drug treatment. The importance of within-subjects evaluation is emphasized.

KW - Adaptive

KW - Behavior

KW - Clinical trial

KW - Cognition

KW - Down syndrome

KW - Drug treatment

KW - Intellectual disability

UR - http://www.scopus.com/inward/record.url?scp=84929305624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929305624&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-16522-6_12

DO - 10.1007/978-3-319-16522-6_12

M3 - Article

VL - 228

SP - 335

EP - 380

JO - Handbook of Experimental Pharmacology

JF - Handbook of Experimental Pharmacology

SN - 0171-2004

ER -